刘小云,赵延延,朱熠冰,李思冬,尹潞,徐波,李卫,王杨

• 1:国家心血管病中心北京协和医学院中国医学科学院阜外医院医学统计部
• 2:国家心血管病中心北京协和医学院中国医学科学院阜外医院介入导管室

摘要(Abstract)：

<正>自21世纪初,经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)心血管疾病的年手术量已逼近八百万的数量级,按2001年开展的577 767例计算,相当于在每100万人口中有1108例进行PCI术,且该数字以每年15%～25%的速度持续增长~([1])。药物洗脱支架(drug-eluting stent, DES)凭借其对支架内再狭窄的有效控制,成为当前PCI的"金标准"~([2])。但有研究表明,DES置入可能导致动脉粥样硬化过程加速、炎症反应和支架小梁断裂等风险~([3])。

关键词(KeyWords)： 主要终点;晚期管腔丢失;药物洗脱球囊;全降解支架;介入无置入

Abstract:

Keywords:

基金项目(Foundation): 中国医学科学院医学与健康科技创新工程经费资助（2016-12M-2-004）

作者(Author): 刘小云,赵延延,朱熠冰,李思冬,尹潞,徐波,李卫,王杨

参考文献(References)：

• [1] Rotter M, Pfiffner D, Maier W,et al. Interventional cardiology in Europe 1999. Eur Heart J,2003,24(12):1164-1170.
• [2] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization:the task force on myocardial revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI). Eur Heart J,2014,35(37):2541-2619.
• [3] Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis:overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J,2015,36(32):2147-2159.
• [4] Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimuseluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORBⅡ）：an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet,2015,385(9962):43-54.
• [5] SabatéM, Windecker S, I?iguez A,et al.Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction:results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J,2016,37(3):229-240.
• [6] Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol,2015,65(8):791-801.
• [7] Kimura T, Kozuma K, Tanabe K,et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimuseluting metallic stents in patients with coronary artery disease:ABSORB Japan. Eur Heart J,2015,36(47):3332-3342.
• [8] Gao R, Yang Y, Han Y, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease:ABSORB China trial. J Am Coll Cardiol,2015,66(21):2298-2309.
• [9] Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med,2015,373(20):1905-1915.
• [10] Cassese S, Byrne RA, Ndrepepa G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents:a meta-analysis of randomised controlled trials. Lancet,2016,387(10018):537-544.
• [11]阚亚柏，韩战营，王徐乐.药物涂层球囊在ST段抬高型心肌梗死患者中的应用现状.中国介入心脏病学杂志，2018, 26(5):289-291.
• [12] Waliszewski M, Rittger H. Surrogate and clinical endpoints in interventional cardiology:are statistics the brakes? Ther Adv Cardiovasc Dis,2016,10(5):314-326.
• [13] Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med,1994,331(8):489-495.
• [14] Kastrati A, Mehilli J, Pache J,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med,2007,356(10):1030-1039.
• [15] Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents:a collaborative network metaanalysis. Lancet,2007,370(9591):937-948.
• [16] Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis:a network meta-analysis. Lancet,2015,386(9994):655-664.
• [17] Stefanini GG, Baber U, Windecker S, et al. Safety and efficacy of drug-eluting stents in women:a patient-level pooled analysis of randomised trials. Lancet,2013,382(9908):1879-1888.
• [18] Palmerini T, Biondi-Zoccai G, Della Riva D,et al. Stent thrombosis with drug-eluting and bare-metal stents:evidence from a comprehensive network meta-analysis. Lancet,2012,379(9824):1393-1402.
• [19] Taniwaki M, Stefanini GG, Silber S, et al. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents:a report from the RESOLUTE All-Comers trial(A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol,2014,63(16):1617-1625.
• [20] Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart,2014,100(2):153-159.
• [21] Go AS, Mozaffarian D, Roger VL,et al. Heart disease and stroke statistics--2014 update:a report from the American Heart Association. Circulation,2014,129(3):e28-e292.
• [22] Silber S. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies? J Interv Cardiol,2004,17(6):375-385.
• [23] Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents:two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions(SPIRIT）Ⅲtrial. Circulation,2009,119(5):680-686.
• [24] Weisz G, Leon MB, Holmes DR Jr, et al. Two-year outcomes after sirolimus-eluting stent implantation:results from the SirolimusEluting Stent in de Novo Native Coronary Lesions(SIRIUS)trial.J Am Coll Cardiol,2006,47(7):1350-1355.
• [25] Kereiakes DJ, Ellis SG, Metzger C, et al. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds:The ABSORBⅢTrial. J Am Coll Cardiol,2017,70(23):2852-2862.
• [26] Giacoppo D, Gargiulo G, Aruta P,et al. Treatment strategies for coronary in-stent restenosis:systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880patients. BMJ,2015,51:h5392.
• [27]张铮，高磊，曹丰.光学相干断层成像在药物洗脱支架术后再狭窄治疗中的作用.中国介入心脏病学杂志，2018, 26(7):400-402.
• [28] Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation,2009,119(23):2986-2994.
• [29] Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart,2010,96(16):1291-1296.
• [30] Habara S, Mitsudo K, Kadota K,et al. Effectiveness of paclitaxeleluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv,2011,4(2):149-154.
• [31] Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxeleluting stent in small coronary vessels:the BELLO(Balloon Elution and Late Loss Optimization)study. J Am Coll Cardiol,2012,60(24):2473-2480.
• [32] Rittger H, Brachmann J, Sinha AM, et al. A randomized,multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis:the PEPCAD-DES study. J Am Coll Cardiol,2012,59(15):1377-1382.
• [33] Scheller B, Clever YP, Kelsch B,et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated baloon catheter. JACC Cardiovasc Interv,2012,5(3):323-330.
• [34] Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent(ISAR-DESIRE 3):a randomised, open-label trial. Lancet,2013,381(9865):461-467.
• [35] Xu B, Gao R, Wang J, et al. A prospective, multicenter,randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis:results from the PEPCAD China ISR trial. JACC Cardiovasc Interv,2014,7(2):204-211.
• [36] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents:the RIBSⅣrandomized clinical trial. J Am Coll Cardiol,2015,66(1):23-33.
• [37] Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis:the three-year results of the PEPCADⅡISR study. EuroIntervention,2015,11(8):926-934.
• [38] Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, et al. Comparison of the efficacy of everolimus-eluting stents versus drug-eluting balloons in patients with in-stent restenosis(from the RIBSⅣandⅤRandomized Clinical Trials). Am J Cardiol,2016,117(4):546-554.
• [39] Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, et al. Longterm results of everolimus-eluting stents versus drug-eluting balloons in patients with bare-metal in-stent restenosis:3-year follow-up of the RIBSⅤClinical Trial. JACC Cardiovasc Interv,2016,9(12):1246-1255.
• [40] Kleber FX, Rittger H, Ludwig J,et al. Drug eluting balloons as stand alone procedure for coronary bifurcational lesions:results of the randomized multicenter PEPCAD-BIF trial. Clin Res Cardiol,2016,105(7):613-621.
• [41] Nishiyama N, Komatsu T, Kuroyanagi T, et al. Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease. Inter J Cardiol, 2016, 222:113-118.
• [42] Pleva L, Kukla P, Kusnierova P, et al. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis:the treatment of instent restenosis study. Circ Cardiovasc Interv, 2016, 9(4):e003316.
• [43] Scheller B, Fontaine T, Mangner N, et al. A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis:Results from the multi-center randomized controlled PATENT-C first in human trial. Catheter Cardiovasc Interv, 2016, 88(1):51-59.
• [44] Funatsu A, Nakamura S, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel disease. Clin Res Cardiol,2017, 106(10):824-832.
• [45] Gobi?D, Tomuli?V, Luli?D, et al. Drug-coated balloon versus drug-eluting stent in primary percutaneous coronary intervention:A feasibility study. Am J Med Sci, 2017, 354(6):553-560.
• [46] Tang Y, Qiao SB, Su X, et al. Drug-coated balloon versus drugeluting stent for small-vessel disease:The RESTORE SVD China Randomized Trial. JACC Cardiovasc Interv, 2018, 11(23):2381-2392.
• [47] Tang YD, Qiao SB, Su X, et al. The effectiveness and safety of the RESTORE((R))drug-eluting balloon versus a drug-eluting stent for small coronary vessel disease:study protocol for a multicenter, randomized, controlled trial. J Geriatr Cardiol,2018, 15(7):469-475.
• [48] Wong YTA, Kang DY, Lee JB, et al. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis:A randomized RESTORE trial. Am Heart J, 2018, 197:35-42.
• [49] Claessen BE, Henriques JPS, Vendrik J, et al. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes melitus and in-stent restenosis:insights from the randomized DARE trial. Catheter Cardiovasc Interv, 2019, 93(2):216-221.
• [50] Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metalic stent for the treatment of coronary artery stenosis(ABSORBⅡ）：a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet, 2016, 388(10059):2479-2491.
• [51] Tenekecioglu E, Serruys PW, Onuma Y, et al. Randomized comparison of absorb bioresorbable vascular scaffold and mirage microfiber sirolimus-eluting scaffold using multimodality imaging.JACC Cardiovasc Interv,2017, 10(11):1115-1130.
• [52] Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med, 2017,376(24):2319-2328.
• [53] Yamaji K, Brugaletta S, SabatéM, et al. Effect of post-dilatation following primary PCI with everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stent implantation:an angiographic and optical coherence tomography TROFIⅡsubstudy.JACC Cardiovasc Interv, 2017, 10(18):1867-1877.
• [54] Han Y, Xu B, Fu G, et al. A randomized trial comparing the Neo Vas sirolimus-eluting bioresorbable scaffold and metallic everolimuseluting stents. JACC Cardiovasc Interv, 2018, 11(3):260-272.
• [55] Stone GW, Ellis G, Gori T, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds:30-day and 1-year results from the ABSORBⅣrandomised trial. Lancet, 2018, 392(10157):1530-1540.
• [56] Giannini F,Latib A, Jabbour RJ, et al. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients-results from the BELLO(baloon elution and late loss optimization)trial. Cardiovasc Revasc Med, 2017, 18(1):4-9.
• [57] Mauri L, Orav EJ, O’Malley AJ, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents.Circulation, 2005, 111(3):321-327.
• [58] Mauri L, Orav EJ, Candia SC, et al. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation, 2005, 112(18):2833-2839.
• [59] Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation,2005, 111(25):3435-3442.
• [60] Asano T, Serruys PW, Collet C, et al. Angiographic late lumen loss revisited:impact on long-term target lesion revascularization. Eur Heart J, 2018, 39(36):3381-3389.
• [61] Doostzadeh J, Clark LN, Bezenek S, et al. Recent progress in percutaneous coronary intervention:evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Coron Artery Dis,2010, 21(1):46-56.
• [62] Xu B, Qian J, Ge J, et al. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial:A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. Catheter Cardiovasc Interv,2016, 87(Suppl 1):624-629.